Analyst Ratings for [NVO] Novo Nordisk A/S

3/13/25	Upgrades	Hold Buy	X
NVO Novo Nordisk A/S Kepler
3/3/25	Downgrades	Buy Hold	X
NVO Novo Nordisk A/S Stifel
2/12/25	Initiated	Equal-Weight	X
NVO Novo Nordisk A/S Morgan Stanley
1/6/25	Upgrades	Underperform Mkt Perform	X
NVO Novo Nordisk A/S Bernstein
5/30/24	Initiated	Buy	X
NVO Novo Nordisk A/S Goldman
$156
4/12/24	Initiated	Outperform	X
NVO Novo Nordisk A/S BMO Capital Markets
$163
1/23/24	Initiated	Overweight	X
NVO Novo Nordisk A/S Morgan Stanley
$120
1/16/24	Resumed	Neutral	X
NVO Novo Nordisk A/S UBS
12/1/23	Initiated	Overweight	X
NVO Novo Nordisk A/S Cantor Fitzgerald
$120
10/2/23	Initiated	Buy	X
NVO Novo Nordisk A/S Argus
$110
7/14/23	Initiated	Buy	X
NVO Novo Nordisk A/S HSBC Securities
7/15/22	Upgrades	Eq-Weight Overweight	X
NVO Novo Nordisk A/S Morgan Stanley
6/28/22	Downgrades	Neutral Sell	X
NVO Novo Nordisk A/S UBS
6/27/22	Upgrades	Underperform Neutral	X
NVO Novo Nordisk A/S Exane BNP Paribas
6/7/22	Upgrades	Neutral Overweight	X
NVO Novo Nordisk A/S JP Morgan
5/31/22	Upgrades	Neutral Buy	X
NVO Novo Nordisk A/S Guggenheim
4/25/22	Upgrades	Mkt Perform Outperform	X
NVO Novo Nordisk A/S Cowen
$130
4/12/22	Upgrades	Underweight Eq-Weight	X
NVO Novo Nordisk A/S Morgan Stanley
3/16/22	Upgrades	Hold Buy	X
NVO Novo Nordisk A/S Deutsche Bank
1/25/22	Downgrades	Hold Sell	X
NVO Novo Nordisk A/S Liberum
12/20/21	Downgrades	Overweight Neutral	X
NVO Novo Nordisk A/S JP Morgan
1/20/21	Downgrades	Outperform Neutral	X
NVO Novo Nordisk A/S Credit Suisse
1/15/21	Initiated	Buy	X
NVO Novo Nordisk A/S Deutsche Bank
6/20/19	Downgrades	Buy Hold	X
NVO Novo Nordisk A/S Deutsche Bank
6/11/19	Upgrades	Underweight Eq Weight	X
NVO Novo Nordisk A/S Barclays
4/29/19	Upgrades	Neutral Outperform	X
NVO Novo Nordisk A/S Credit Suisse
1/29/19	Initiated	Outperform	X
NVO Novo Nordisk A/S Exane BNP Paribas
12/11/18	Resumed	Hold	X
NVO Novo Nordisk A/S Jefferies
10/9/18	Initiated	Buy	X
NVO Novo Nordisk A/S Guggenheim

NVO Novo Nordisk A/S

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.